MX2011007641A - Nuevos compuestos heterociclicos como inhibidores de metap-2. - Google Patents

Nuevos compuestos heterociclicos como inhibidores de metap-2.

Info

Publication number
MX2011007641A
MX2011007641A MX2011007641A MX2011007641A MX2011007641A MX 2011007641 A MX2011007641 A MX 2011007641A MX 2011007641 A MX2011007641 A MX 2011007641A MX 2011007641 A MX2011007641 A MX 2011007641A MX 2011007641 A MX2011007641 A MX 2011007641A
Authority
MX
Mexico
Prior art keywords
inhibitors
metap
heterocyclic compounds
novel heterocyclic
compounds
Prior art date
Application number
MX2011007641A
Other languages
English (en)
Inventor
Timo Heinrich
Frank Zenke
Kai Schiemann
Mireille Krier
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2011007641A publication Critical patent/MX2011007641A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Los compuestos de la fórmula I.(ver fórmula(I)) en donde D, X, Y, Z, R y R1 tienen los significados indicados en la reivindicación 1, son inhibidores de la metionina-amino-peptidasa y se pueden usar para el tratamiento de tumores.
MX2011007641A 2009-01-20 2009-12-22 Nuevos compuestos heterociclicos como inhibidores de metap-2. MX2011007641A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102009005193A DE102009005193A1 (de) 2009-01-20 2009-01-20 Neue heterocyclische Verbindungen als MetAP-2 Inhibitoren
PCT/EP2009/009218 WO2010083870A1 (de) 2009-01-20 2009-12-22 Neue heteroclyclische verbindungen als metap-2 inhibitoren

Publications (1)

Publication Number Publication Date
MX2011007641A true MX2011007641A (es) 2011-09-06

Family

ID=42210278

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011007641A MX2011007641A (es) 2009-01-20 2009-12-22 Nuevos compuestos heterociclicos como inhibidores de metap-2.

Country Status (16)

Country Link
US (1) US8546406B2 (es)
EP (1) EP2379558B1 (es)
JP (1) JP5619025B2 (es)
KR (1) KR20110112434A (es)
CN (1) CN102292339B (es)
AR (1) AR075035A1 (es)
AU (1) AU2009337953B2 (es)
BR (1) BRPI0924033A2 (es)
CA (1) CA2749970C (es)
DE (1) DE102009005193A1 (es)
EA (1) EA201101090A1 (es)
ES (1) ES2575687T3 (es)
IL (1) IL213935A (es)
MX (1) MX2011007641A (es)
SG (1) SG174118A1 (es)
WO (1) WO2010083870A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102008027574A1 (de) * 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren
BR112021014220A2 (pt) * 2019-01-22 2022-01-18 Merck Patent Gmbh Derivados heterocíclicos
US20250304625A1 (en) * 2022-04-06 2025-10-02 Vanderbilt University Articles and methods for inhibiting methionine aminopeptidase activity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3037980A (en) * 1955-08-18 1962-06-05 Burroughs Wellcome Co Pyrrolopyrimidine vasodilators and method of making them
FR2448542A1 (fr) * 1979-02-06 1980-09-05 Landerlan Sa Lab Derives de triazolapyrimidine utiles comme medicaments
US5747469A (en) 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
EP0831829B1 (en) * 1995-06-07 2003-08-20 Pfizer Inc. Heterocyclic ring-fused pyrimidine derivatives
US6395733B1 (en) * 1995-06-07 2002-05-28 Pfizer Inc Heterocyclic ring-fused pyrimidine derivatives
PA8474101A1 (es) * 1998-06-19 2000-09-29 Pfizer Prod Inc Compuestos de pirrolo [2,3-d] pirimidina
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
UY26664A1 (es) 2000-04-14 2001-11-30 Abbott Lab Hidrazidas y alcoxiamidas inhibidoras de la angiogénesis.
US20070161570A1 (en) 2000-11-01 2007-07-12 Praecis Pharmaceuticals, Inc. Methionine aminopeptidase-2 inhibitors and methods of use thereof
JP2004535377A (ja) 2001-04-03 2004-11-25 スミスクライン・ビーチャム・コーポレイション Ｍｅｔａｐ２を阻害する方法
JP4306206B2 (ja) * 2001-09-04 2009-07-29 住友化学株式会社 イミダゾ［１，２−ａ］ピリミジン、その用途およびその製造中間体
WO2004108136A1 (en) * 2003-06-04 2004-12-16 Vernalis (Cambridge) Limited Triazolo `1 , 5-a!pyrimidines and their use in medicine
CN1933844A (zh) * 2003-12-22 2007-03-21 吉里德科学公司 激酶抑制剂膦酸酯缀合物
US20050187389A1 (en) * 2004-01-13 2005-08-25 Ambit Biosciences Corporation Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases
AR053090A1 (es) * 2004-07-20 2007-04-25 Osi Pharm Inc Imidazotriazinas como inhibidores de proteina quinasas y su uso para la preparacion de medicamentos
AU2006227790B2 (en) * 2005-03-15 2009-09-10 Irm Llc Compounds and compositions as protein kinase inhibitors
DE102005037733A1 (de) 2005-08-10 2007-02-15 Merck Patent Gmbh Adeninderivate
WO2008012635A2 (en) * 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
DE102008027574A1 (de) * 2008-06-10 2009-12-17 Merck Patent Gmbh Neue Pyrrolidinderivate als MetAP-2 Inhibitoren

Also Published As

Publication number Publication date
AU2009337953A1 (en) 2011-09-01
CA2749970A1 (en) 2010-07-29
EP2379558A1 (de) 2011-10-26
CA2749970C (en) 2017-11-28
IL213935A0 (en) 2011-07-31
SG174118A1 (en) 2011-10-28
IL213935A (en) 2017-06-29
KR20110112434A (ko) 2011-10-12
CN102292339B (zh) 2015-01-28
AR075035A1 (es) 2011-03-02
EA201101090A1 (ru) 2012-03-30
US8546406B2 (en) 2013-10-01
JP2012515731A (ja) 2012-07-12
CN102292339A (zh) 2011-12-21
BRPI0924033A2 (pt) 2016-01-26
JP5619025B2 (ja) 2014-11-05
US20110281859A1 (en) 2011-11-17
ES2575687T3 (es) 2016-06-30
WO2010083870A1 (de) 2010-07-29
DE102009005193A1 (de) 2010-07-22
AU2009337953B2 (en) 2016-02-11
EP2379558B1 (de) 2016-03-23

Similar Documents

Publication Publication Date Title
WO2010003475A8 (de) Neue pyrrolidinderivate als metap-2 inhibitoren
MX2013004004A (es) Pirrolidinonas como inhibidores de metionina aminopeptidasa (metap-2).
PH12014501964A1 (en) Cyclic amides as metap-2 inhibitors
MX2010009416A (es) Compuestos heterociclicos como inhibidores de cxcr2.
MX2011011094A (es) Derivados de prolina como inhibidores de catepsina.
MX336381B (es) Boronatos como inhibidores de arginasa.
MX2012006805A (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa.
MX340714B (es) Inhibidores de hsp90.
MY155517A (en) Heterocyclic derivatives
MY160454A (en) Oxazole substituted indazoles as pi3-kinase inhibitors
NZ597517A (en) 5-fluoropyrimidinone derivatives
EA201200119A1 (ru) Гетероциклические соединения в качестве ингибиторов аутотаксина
EA201100880A1 (ru) Бензонафтиридиновые соединения в качестве ингибиторов аутотаксина
NZ589844A (en) Thiophene or thiazole derivatives and their use as phosphatidylinositol 3-kinase (PI3K) inhibitors
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
EA201170832A1 (ru) Пуриновые соединения
EA201200323A1 (ru) Соединения и композиции, как ингибиторы протеинкиназы
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
MX2010010406A (es) Tetrahidrofenantridinonas y tetrahidrociclopentaquinolinonas como inhibidores de la polimerizacion de poli(adp-ribosa)polimerasa-1 y tubulina.
MX345127B (es) Derivados de tiazol.
MX2010003365A (es) Derivados de tiazol para el tratamiento de cancer.
NZ597483A (en) N1-substituted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
NZ597570A (en) N1-acyl-5-fluoropyrimidinone derivatives
WO2011047055A8 (en) Novel mek inhibitors, useful in the treatment of diseases
MX2012000177A (es) 2-carboxamida-cicloamino-ureas sustituidas.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal